Evidence map›Paper›PMID 38789634›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2024

The use of new antibacterial drugs against infections caused by multidrug-resistant Gram-negative bacteria: an Italian real-world evidence study in a Lombardy hospital.

Francesco Ferrara, Roberta Pasquinucci, Anna Chiara Aloisi, Giacomo Polito, Gabriele Bagaglini, Maurizio Capuozzo, Andrea Zovi

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Francesco FerraraPharmaceutical Department, Asl Napoli 3 Sud, Dell'amicizia Street 22, 80035, Nola, Naples, Italy. f.ferrara@aslnapoli3sud.it.ORCID 0000-0001-9298-6783
Roberta PasquinucciPharmaceutical Department, Asl Napoli 3 Sud, Dell'amicizia Street 22, 80035, Nola, Naples, Italy.
Anna Chiara AloisiFondazione IRCCS San Gerardo dei Tintori di Monza, G.B. Pergolesi Street 33, 2900, Monza, Italy.
Giacomo PolitoPharmacy Unit, Policlinico Umberto I Hospital, del Policlinico Street 155, 00161, Rome, Italy.
Gabriele BagagliniPharmacy Unit, ASL Latina, Pier Luigi Nervi Street, 04100, Latina, Italy.
Maurizio CapuozzoPharmaceutical Department, Asl Napoli 3 Sud, Marittima Street 3, 80056, Ercolano, Naples, Italy.ORCID 0000-0001-9488-6057
Andrea ZoviMinistry of Health, Viale Giorgio Ribotta 5, 00144, Rome, Italy.ORCID 0000-0002-6528-2171

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infections caused by multidrug-resistant (MDR) bacteria are typically associated with high morbidity and mortality, especially in vulnerable individuals such as patients with prolonged hospitalizations, immunocompromised individuals, and the elderly. This study aimed to provide post-marketing surveillance results concerning the prevalence of antibiotic resistance against Gram-negative bacteria through the collaboration of a multidisciplinary team. Patients involved have been treated with new antibacterial drugs, in particular ceftazidime/avibactam (C/A), meropenem/vaborbactam (M/V), cefiderocol, and ceftolozane/tazobactam (C/T). The most resistant bacterial species were Klebsiella spp., Pseudomonas aeruginosa, and Acinetobacter baumannii. Italian Drug Agency (AIFA) monitoring records for inpatients have been collected and analyzed, assessing the characteristics of the patients involved. Adverse drug reactions (ADRs) and drugs involved have been reported using a descriptive analytical approach. All data have been collected retrospectively from patient's medical records and entered into an electronic case report form (CRF). Among the 104 treated patients, Klebsiella spp. accounted for 50.1% of infections, Pseudomonas aeruginosa for 32.7%, Acinetobacter baumannii for 3%, and other bacterial species for 1.92% configuring polymicrobial infections. Regarding treatment outcomes, healing was achieved in 61 (58.6%) patients, 23 (22.1%) patients died, 8 (7.7%) patients discontinued empirical therapy, and 3 (2.9%) patients were lost to follow-up. Despite the introduction of new antibacterial drugs active against Gram-negative bacteria is improving the clinical scenario, it is crucial that the use of new antibacterial drugs be implemented by appropriate antimicrobial stewardship, surveillance programs, and monitoring efforts to prevent further spread of resistance. This study showed that the new antibiotics have good efficacy against MDR bacteria and cause negligible side effects.

Indexed as

Anti-Bacterial AgentsDrug Resistance, Multiple, BacterialGram-Negative BacteriaGram-Negative Bacterial InfectionsAdolescentAdultAgedAged, 80 and overAzabicyclo CompoundsCeftazidimeCephalosporinsDrug CombinationsFemaleHumansItalyMaleAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsCeftazidimeceftolozane, tazobactam drug combinationCephalosporinsDrug CombinationsTazobactamAntibiotic resistanceAntimicrobial stewardshipAssessmentConsumptionDefined daily dose

Identifiers

PMID38789634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.